Nafarelin in the treatment of endometriosis. Dose management
Other
OA: bronze
CC0
⤵ 8 in-corpus citations
AI-generated summary
Nafarelin, a GnRH agonist, effectively treats endometriosis, with side effects manageable by monitoring estrogen status and adjusting the standard 200 mcg bid intranasal dosage.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Nafarelin, a gonadotropin-releasing hormone agonist, has been shown to be effective in the treatment of endometriosis. The standard dosage is 200 micrograms bid intranasally. Side effects most commonly include those associated with estrogen deprivation. By assessing estrogen status, the standard dosage can be manipulated to minimize these side effects and increase patient compliance.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (3)
- Gonadotropin-releasing hormone agonists: strategies for managing the hypoestrogenic effects of therapy via openalex
- W2125350310 via openalex
- W2289447244 via openalex
Cited by (8)
- Agonists of gonadotropin-releasing-hormone and add-back-therapy 2023
- Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not? 2023
- GnRH-Analoga und Add-back-Verfahren 2008
- Medical Management of Endometriosis 2008
- Gonadotropin Releasing Honnone Agonist and Antagonist for Endometriosis 2003
- Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy) 2000
- Many hormonal treatments to choose from for endometriosis 2000
- Current drug therapy recommendations for the treatment of endometriosis 1999
Source provenance
- europepmc
- last seen: 2026-10-17T06:09:56.316927+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:59:14.651011+00:00
License: CC0
· commercial use OK